NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Quince Therapeutics, Inc. (QNCX) Stock Analysis

Quince Therapeutics, Inc. (QNCX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 20, 2026

QNCX

$40.27

+$5.82 (+16.89%)

Oct 20, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QNCX with… →

QNCX Key Statistics

As of Oct 20, 2026
Trading
Open
$34.99
Previous Close
$34.45
Day's Range
34.79–41.00
52-Week Range
15.10–910.00
Volume
317.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.33
Valuation
Market Cap
$32.27M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−214.01
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$83.98M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.02M
1-Year Return
−89.12%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
29.96K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 20, 2026, QNCX closed at $40.27, −89.12% over 1 year.

Quince Therapeutics, Inc. (QNCX) has a market capitalization of $32.27M.

In fiscal 2025, QNCX reported revenue of $0.00.

QNCX Stock Return by Calendar Year

Quince Therapeutics, Inc. (QNCX) return since May 2019: what $10,000 became

1 year
$10,000 $1,088
−89.12%
5 years
$10,000 $35
−99.65%
Since May 2019
$10,000 $61
−99.39%

If you had invested $10,000 in Quince Therapeutics, Inc. (QNCX) at the close on May 9, 2019, the earliest close on record here, it would have been worth $61 at the close on October 20, 2026: −99.39% in total, −49.54% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−93.99%
2025+79.14%
2024+78.10%
2023+64.84%
2022−94.95%
2021−54.57%
2020−50.52%
2019 (partial year)+70.69%

As of October 20, 2026.

QNCX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$83.98M—
2024$0.00−$56.83M—
2023$0.00−$31.39M—
2022$0.00−$51.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$50.43M−$83.98M—
2024$0.00—−$36.17M−$56.83M—
2023$0.00—−$27.14M−$31.39M—
2022$0.00—−$51.19M−$51.66M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Quince Therapeutics, Inc. (QNCX) is capitalised at $32.27M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 38.

The most recent close on file for QNCX is $40.27, dated October 20, 2026. That is +$5.82 (+16.89%) against the previous close. The 52-week range on file runs from $15.10 to $910.00. The latest close sits 166.69% above that 52-week low.

Financial Health

In fiscal 2025, Quince Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $83.98M. Earnings per share on a trailing basis come to −214.01.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.33. Annualized volatility over the trailing 7 years is 162.3%. The trailing one-year total return is −89.12%. Across 5 years the annualized return works out at −67.79%.

Growth & Income

The record shows no dividend for QNCX.

So far in 2026 the total return is −93.99%. The strongest complete calendar year on file is 2025 at +79.14%; the weakest is 2022 at −94.95%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

Quince Therapeutics, Inc. (QNCX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Quince Therapeutics, Inc. QNCX $32.27M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Quince Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 20, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Visit website →